Back to results
US 11,884,979 B2Granted
RNA biomarkers for hereditary angioedema
AssigneeTakeda Pharmaceutical Company Limited
InventorsDaniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Claims26
A method for analyzing a sample, comprising:
- (i) providing a biological sample obtained from a subject having, suspected of having, or being at risk for hereditary angioedema (HAE);
- (ii) measuring the level of a RNA biomarker set, wherein the RNA biomarker set comprises a messenger RNA encoding mitochondrially-encoded cytochrome C oxidase III (MT-CO3);
- (iii) identifying the subject as a subject having HAE based on the level of the RNA biomarker set, an increase of the level of MT-CO3 of the subject from that of a control subject being indicative of the subject having HAE;
- and
- (iv) administering to the subject identified as having HAE in step (iii) an effective amount of a therapeutic agent for treating HAE;
- wherein the therapeutic agent is a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor (B2R) inhibitor, and/or a Cl esterase inhibitor.
3 more elements
A method for analyzing a sample, comprising:
- (i) providing a biological sample obtained from a subject having, suspected of having, or being at risk for hereditary angioedema (HAE);
- (ii) measuring the level of a RNA biomarker set, wherein the RNA biomarker set comprises a messenger RNA encoding mitochondrially-encoded cytochrome C oxidase III (MT-CO3);
- (iii) identifying the subject as a subject at risk of HAE attack based on the level of the RNA biomarker set, an increase of the level of MT-CO3 of the subject from that of a control subject being indicative that the subject is at risk of HAE attack;
- and
- (iv) administering to the subject identified as being at risk of HAE attack in step (iii) an effective amount of a therapeutic agent,
- wherein the therapeutic agent is a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor (B2R) inhibitor, and/or a Cl esterase inhibitor.
3 more elements
Dependencies are inferred from the claim text.